Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing gram-negative bacteria: How to define the best treatment regimen?

Clinical Infectious Diseases

Volumn 60, Issue 9, 2015, Pages 1326-1329

  Perez, Federico ^a,b   Bonomo, Robert A ^a,b  

^a Affairs Medical Center   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bloodstream infection; Carbapenems; Extended spectrum lactamases; lactam lactamase inhibitor combinations

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AVIBACTAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; RELEBACTAM; TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID;

BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION RISK; KLEBSIELLA; KLEBSIELLA OXYTOCA; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NOTE; PRIORITY JOURNAL; PROTEUS; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BACTEREMIA; ENTEROBACTERIACEAE INFECTIONS; FEMALE; MALE; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; PENICILLANIC ACID;

EID: 84928892352     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ007     Document Type: Note

References (25)

1. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54:969-76.
2. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and ce-furoxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11:315-7.
3. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteria-ceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-66.
4. Petty NK, Ben Zakour NL, Stanton-Cook M, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci USA 2014; 111:5694-9.
5. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
6. Huang Y, Carroll KC, Cosgrove SE, Tamma PD. Determining the optimal ceftriaxone MIC for triggering extended-spectrum beta-lactamase confirmatory testing. J Clin Micro-biol 2014; 52:2228-30.
7. Gheorghiu R, Yuan M, Hall LM, Livermore DM. Bases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hy-perproducing K1 beta-lactamase. J Antimi-crob Chemother 1997; 40:533-41.
8. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
9. Thomson KS, Moland ES. Cefepime, pipera-cillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lacta-mase-producing Enterobacteriaceae. Antimi-crob Agents Chemother 2001; 45:3548-54.
10. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother 2002; 50:425-8.
11. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefe-pime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488-95.
12. Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemo-ther 2012; 56:3936-42.
13. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7.
14. Hilty M, Sendi P, Seiffert SN, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents 2013; 41:236-49.
15. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteria-ceae. Clin Infect Dis 2013; 57:781-8.
16. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010; 23:160-201.
17. Lopez-Cerero L, Picon E, Morillo C, et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-produc-ing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 2010; 16:132-6.
18. Ambrose PG, Bhavnani SM, Jones RN. Phar-macokinetics-pharmacodynamics of cefe-pime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003; 47:1643-6.
19. Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsi-ella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006; 50:3179-82.
20. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Entero-bacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-94.
21. Rodríguez-Baño J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54:167-74.
22. Gutierrez-Gutierrez BS, Salamanca E, Perez-Galera S, et al. Assessment of β-lactam/β-lactam inhibitor (BL/BLI) combinations for the treatment of bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae: The INCREMENT project. Abstract K 1041. In: Interscience Conference on Antmicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2014.
23. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. Prevalence of beta-lactamase-encoding genes among Enterobac-teriaceae bacteremia isolates collected in 26 U. S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimic-rob Agents Chemother 2013; 57:3012-20.
24. Rodriguez-Bano J, Mingorance J, Fernandez-Romero N, Serrano L, Lopez-Cerero L, Pascual A. Virulence profiles of bacteremic extended-spectrum beta-lactamase-producing Escherichia coli: association with epidemio-logical and clinical features. PloS One 2012; 7:e44238.
25. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimi-crob Agents Chemother 2012; 56:544-9.